Integer Holdings Co. (NYSE:ITGR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Integer Holdings Co. (NYSE:ITGR) have earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $133.86.

A number of equities research analysts recently commented on the company. Benchmark reiterated a “buy” rating and issued a $130.00 price objective on shares of Integer in a report on Friday, August 2nd. Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price target for the company.

Insider Transactions at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the transaction, the director now directly owns 2,280 shares of the company’s stock, valued at $272,824.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Xponance Inc. boosted its position in shares of Integer by 4.9% during the second quarter. Xponance Inc. now owns 2,112 shares of the medical equipment provider’s stock worth $245,000 after buying an additional 99 shares during the period. Quadrant Capital Group LLC boosted its position in Integer by 10.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 132 shares during the last quarter. GAMMA Investing LLC boosted its position in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Integer by 3.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 5,948 shares of the medical equipment provider’s stock valued at $689,000 after purchasing an additional 205 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in Integer by 2.4% during the second quarter. Arizona State Retirement System now owns 9,378 shares of the medical equipment provider’s stock valued at $1,086,000 after purchasing an additional 219 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Trading Down 1.0 %

NYSE ITGR opened at $127.09 on Wednesday. The stock has a 50-day simple moving average of $123.20 and a 200 day simple moving average of $118.83. The company has a market capitalization of $4.26 billion, a PE ratio of 43.98, a P/E/G ratio of 1.81 and a beta of 1.09. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.73. Integer has a 12 month low of $69.40 and a 12 month high of $131.87.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to the consensus estimate of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 earnings per share. Research analysts forecast that Integer will post 5.31 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.